Phase 3 Recruiting Academic/Other
This phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monocl…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT03150693
Sites in California: - Kaiser Permanente-Deer Valley Medical Center — Antioch, California
- PCR Oncology — Arroyo Grande, California
- Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
- Community Cancer Institute — Clovis, California
- University Oncology Associates — Clovis, California
Phase 3 Recruiting NIH
This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stag…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05675410
Sites in California: - Mercy Cancer Center - Carmichael — Carmichael, California
- Mercy San Juan Medical Center — Carmichael, California
- City of Hope Corona — Corona, California
- UC Irvine Health Cancer Center-Newport — Costa Mesa, California
- Kaiser Permanente Downey Medical Center — Downey, California
Phase 3 Recruiting Network
This phase III trial compares the effect of high dose chemotherapy and the patients' own (autologous) stem cells to observation only in patients with peripheral T-cell lymphoma who achieved a complete response after initial chemotherapy. U…
Sponsor: Eastern Cooperative Oncology Group
NCT ID: NCT06724237
Sites in California: - Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
- City of Hope Comprehensive Cancer Center — Duarte, California
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
- Contra Costa Regional Medical Center — Martinez, California
- Providence Queen of The Valley — Napa, California
Phase 3 Recruiting Industry
The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of son…
Sponsor: BeOne Medicines
NCT ID: NCT06742996
Sites in California: - Ucsf Fresno — Fresno, California
- Kaiser Permanente Southern California — Irvine, California
Phase 3 Recruiting Industry
The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). …
Sponsor: BeOne Medicines
NCT ID: NCT06943872
Sites in California: - Uci Health Laguna Hills — Laguna Hills, California
- Chao Family Comprehensive Cancer Center — Orange, California
- Stanford Cancer Institute — Palo Alto, California
- Scripps Prebys Cancer Center — San Diego, California
Phase 3 Recruiting Industry
The study is designed as a multicenter, randomized, open label Phase 3 study to compare the efficacy and safety of golcadomide in combination with rituximab vs investigator's choice in participants with relapsed/refractory follicular lymph…
Sponsor: Celgene
NCT ID: NCT06911502
Sites in California: - City of Hope Comprehensive Cancer Center — Duarte, California
- UCSF Helen Diller Medical Center at Parnassus Heights — San Francisco, California
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refracto…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06084936
Sites in California: - Alta Bates Summit Medical Center — Berkeley, California
- City of Hope Cancer Center — Duarte, California
- Valkyrie Clinical Trials — Los Angeles, California
- University of California Los Angeles (UCLA) - Cancer Care - Santa Monica — Santa Monica, California
Phase 3 Recruiting Industry
The purpose of this clinical trial is to evaluate efficacy and safety of tirabrutinib alone compared with rituximab and temozolomide (R-TMZ) combination therapy in participants with Relapsed/Refractory Primary Central Nervous System Lympho…
Sponsor: Ono Pharmaceutical Co., Ltd.
NCT ID: NCT07104032
Sites in California: - Providence Medical Foundation — Fullerton, California
- UC Irvine Health — Orange, California
Phase 3 Recruiting Industry
Multicenter, randomized, controlled, open-label, Phase 3 study designed to demonstrate that neladalkib (NVL-655) is superior to alectinib in prolonging progression-free survival (PFS) in patients with treatment-naïve, Anaplastic Lymphoma K…
Sponsor: Nuvalent Inc.
NCT ID: NCT06765109
Sites in California: - Hoag Hospital Newport Beach — Newport Beach, California
- University of California, Irvine Health — Orange, California
Phase 3 Recruiting Industry
The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part …
Sponsor: Loxo Oncology, Inc.
NCT ID: NCT05254743
Sites in California: - Pacific Cancer Medical Center, Inc — Anaheim, California
- TOI Clinical Research — Cerritos, California
- Stanford School of Medicine-Cancer Clinical Trials Office — Palo Alto, California
- California Cancer Associates for Research and Excellence — San Marcos, California
Phase 3 Recruiting Industry
This is a global multicenter, open label, randomized, registrational phase III study to investigate the efficacy and safety of lisaftoclax in combination with BTK inhibitors in CLL/SLL patients who previously treated with BTK inhibitors
Sponsor: Ascentage Pharma Group Inc.
NCT ID: NCT06104566
Sites in California: - Ascentage Investigative Site — Anaheim, California
Phase 3 Recruiting Industry
The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrut…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT05947851
Sites in California: - MemorialCare Health System - Long Beach Medical Center ( Site 5421) — Long Beach, California
Phase 2 Recruiting NIH
This phase II trial studies how well inotuzumab ozogamicin and blinatumomab with or without ponatinib work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back after a period…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03739814
Sites in California: - PCR Oncology — Arroyo Grande, California
- Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
- Community Cancer Institute — Clovis, California
- University Oncology Associates — Clovis, California
- City of Hope Comprehensive Cancer Center — Duarte, California
Phase 2 Recruiting Academic/Other
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE:…
Sponsor: American Society of Clinical Oncology
NCT ID: NCT02693535
Sites in California: - Sutter Auburn — Auburn, California
- Sutter Alta Bates — Berkeley, California
- The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate — Los Angeles, California
- Kaiser Permanente - Oakland Medical Center — Oakland, California
- Sutter Palo Alto Medical Foundation: Palo Alto — Palo Alto, California
Phase 1, Phase 2 Recruiting Network
This phase I/II trial studies the safety, side effects and best dose of OBI-3424 and how well it works in treating patients with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back (relapsed) or does not…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT04315324
Sites in California: - PCR Oncology — Arroyo Grande, California
- City of Hope Comprehensive Cancer Center — Duarte, California
- Loma Linda University Medical Center — Loma Linda, California
- Children's Hospital of Orange County — Orange, California
Phase 2 Recruiting NIH
This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in California: - Loma Linda University Medical Center — Loma Linda, California
- Miller Children's and Women's Hospital Long Beach — Long Beach, California
- UCSF Benioff Children's Hospital Oakland — Oakland, California
- Kaiser Permanente-Oakland — Oakland, California
- Children's Hospital of Orange County — Orange, California
Phase 2 Recruiting Network
This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleuce…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05633615
Sites in California: - UC Irvine Health Cancer Center-Newport — Costa Mesa, California
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
- UCI Health Laguna Hills — Laguna Hills, California
- UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California
- UCSF Medical Center-Parnassus — San Francisco, California
Phase 2 Recruiting NIH
This phase II trial compares mosunetuzumab to the usual treatment (rituximab) for improving survival in patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). Rituximab and mosunetuzumab are monoclonal antibodies. They bind…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05886036
Sites in California: - City of Hope Comprehensive Cancer Center — Duarte, California
Phase 1, Phase 2 Recruiting Industry
A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.
Sponsor: Sumitomo Pharma America, Inc.
NCT ID: NCT04988555
Sites in California: - Hoag Family Cancer Center — Newport Beach, California
- Stanford University — Palo Alto, California
Phase 2 Recruiting Industry
This Phase II trial evaluates the optimization of the cytokine release syndrome (CRS) profile for glofitamab in combination with gemcitabine and oxaliplatin (Glofit-GemOx) in participants with relapsed or refractory aggressive B-cell Non-H…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06806033
Sites in California: - Community Cancer Institute (CCI) — Clovis, California
- Providence Medical Foundation — Fullerton, California
- Los Angeles Cancer Network — Glendale, California
- Valkyrie Clinical Trials — Los Angeles, California
- Valkyrie Clinical Trials — Panorama City, California
Phase 1, Phase 2 Recruiting Industry
Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)
Sponsor: BeOne Medicines
NCT ID: NCT05006716
Sites in California: - University of California San Diego (Ucsd) Moores Cancer Center — La Jolla, California
- Stanford Medicine — Palo Alto, California
- UCLA Santa Monica Cancer Care — Santa Monica, California
Phase 1, Phase 2 Recruiting Industry
This is a multi-center, open-label study to evaluate the safety, pharmacokinetics (PK), and anti-cancer activity of oral administration of emavusertib alone or in combination with ibrutinib in adult participants with relapsed or refractory…
Sponsor: Curis, Inc.
NCT ID: NCT03328078
Sites in California: - City of Hope — Duarte, California
- Providence St. John's Health Center — Santa Monica, California
- UCLA Department of Medicine - Hematology/Oncology — Santa Monica, California
Phase 2 Recruiting Industry
The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of tre…
Sponsor: Loxo Oncology, Inc.
NCT ID: NCT06588478
Sites in California: - City of Hope National Medical Center — Duarte, California
- City of Hope National Medical Center — Irvine, California
- Palo Alto Medical Foundation Research Institute (PAMFRI) — Palo Alto, California
- Stanford Cancer Center — Palo Alto, California
Phase 2 Recruiting Academic/Other
This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL. Chemotherapy during the firs…
Sponsor: Etan Orgel
NCT ID: NCT05082519
Sites in California: - Children's Hospital Los Angeles — Los Angeles, California
- Children's Hospital Orange County — Orange, California
- UCSF School of Medicine — San Francisco, California
Phase 2 Recruiting Industry
This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclophosphamide (CPA) in subjects with relapsed or refractory DLBCL.
Sponsor: ImmunoVaccine Technologies, Inc. (IMV Inc.)
NCT ID: NCT04920617
Sites in California: - Compassionate Cancer Care Medical Group — Fountain Valley, California